Affidea is Europe’s leading provider of advanced diagnostic imaging, outpatient and cancer care services. The company has a strong track record for patient safety and is recognized by the European Society of Radiology as the continent’s most awarded diagnostic imaging provider.

5.0 %
Portfolio value 03/31/2023
Investment case

Affidea is the leading pan-European player in a large, resilient and attractive market, driven by solid fundamentals:

  • Demand driven by long-term structural tailwinds, including rising demand from an ageing population and increased focus on prevention through diagnostics to reduce the total cost of healthcare
  • Undersupplied market resulting in longer public waiting times for diagnostic services
  • Economy of scale from: (i) sticky long-term contracts with the public sector, (ii) high capital intensity requirements, (iii) complex imaging regulations and licenses required and (iv) radiologist shortage.

In addition, the European market remains largely fragmented, offering numerous M&A opportunities.

Affidea is well positioned with a scalable platform diversified across countries and payors with multiple growth avenues:

  • Local market leadership in the majority of its 15 countries, with exposure to more complex modalities as well as the faster growing private segment
  • Opportunity to further expand service offering and provide outpatient care in a community setting through Affidea’s more than 300 clinics, the majority of which are stand alone
  • Track record of successfully executing and integrating M&A, with 40+ companies acquired since 2014
  • Margin improvement potential from best practice sharing as well as from productivity gains of medical staff
  • Well positioned to benefit from teleradiology and artificial intelligence opportunities

Driving medical excellence and providing quality care have always been at Affidea’s core. Its long-term track record has resulted in Affidea becoming the most awarded diagnostic imaging provider in Europe by the European Society of Radiology.

More recently, the Board and management have been strengthened with new appointments.

  • Board of Directors 4/7*